“We expect that additional US federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the US federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.”
All entries for: Antiviral
November 8, 2023
Atea Pharmaceuticals
Negative Outlook
Boston, MA
51-200 employees
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
November 7, 2023
Gilead
Negative Outlook
Foster City, CA
10,001-50,000 employees
10001-50000 employees
“While the full impact of the Act on our business and the pharmaceutical industry remains uncertain at this time, we anticipate that the Act will increase our payment obligations under the redesigned Part D discount program, limit the prices we can charge for our products, and increase the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results.”
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
August 5, 2023
Atea Pharmaceuticals
Negative Outlook
Boston, MA
51-200 employees
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
August 4, 2023
Gilead
Negative Outlook
Foster City, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
May 5, 2023
Atea Pharmaceuticals
Negative Outlook
Boston, MA
51-200 employees
51-200 employees
Disease Area: Antiviral
Drug Type: Small Molecule
May 3, 2023
Gilead
Negative Outlook
Foster City, CA
10,001-50,000 employees
10001-50000 employees
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
November 7, 2022
Atea Pharmaceuticals
Negative Outlook
Boston, MA
51-200 employees
51-200 employees
Likely Signigifant: “Most significantly, on August 16, 2022, President Biden signed the IRA into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010… For that and other reasons, it is currently unclear how the IRA will be effectuated, and while the impact of the IRA on the pharmaceutical industry and our business cannot yet be fully determined, it is likely to be significant.”
Disease Area: Antiviral
Drug Type: Small Molecule
November 2, 2022
Gilead
Negative Outlook
Foster City, CA
10,001-50,000 employees
10001-50000 employees
• Potential for Limiting Prices, More Rebates: “We are continuing to evaluate the impact of the Act on our business, but it is possible that the Act could have the effect of limiting the prices we can charge and increasing the rebates we must provide government programs for our products, thereby reducing our profitability and negatively impacting our financial results” • Additional Leg/Rulemaking: “We cannot be sure whether additional legislation or rulemaking related to the Act will be issued or enacted, or what impact, if any, such changes will have on the profitability of our business in the future” • Uncertainty: “These initiatives and such other legislation may cause added pricing pressures on our products, and the resulting impact on our business is uncertain”
Disease Area: Antiviral
Drug Type: Biologic, Small Molecule
